{
"id":"mk19_bb_en_s1",
"subspecialtyId":"en",
"title":"Diabetes Mellitus",
"jsonContent":{
"type":"section",
"id":"mk19_bb_en_s1",
"title":{
"__html":"Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"983bb7",
"children":[
"Diabetes Mellitus"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_en_s1_1",
"title":{
"__html":"Type 1 Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"b31a06",
"children":[
"Type 1 Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"daf10f",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Diagnosis"
]
},
" "
]
},
{
"type":"p",
"hlId":"9cbe73",
"children":[
"Type 1 diabetes is characterized by a β-cell destructive process that may eventually lead to absolute insulin deficiency. The onset of type 1 diabetes is typically abrupt and severe and may be associated with a precipitating event, such as infection, pregnancy, or ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"myocardial infarction",
"children":[
"MI"
]
},
"."
]
},
" Look for fatigue, polyuria, polydipsia, blurring of vision, weight loss, and dehydration."
]
},
{
"type":"p",
"hlId":"717111",
"children":[
"More than 90% of cases of type 1 diabetes are autoimmune (type 1A). Measuring antibodies to ",
{
"type":"abbreviation",
"title":"glutamate decarboxylase antibody",
"children":[
"GAD65"
]
},
" and ",
{
"type":"abbreviation",
"title":"islet antigen-2 antibody",
"children":[
"IA-2"
]
},
" is recommended for initial confirmation. Approximately 20% of patients with type 1 diabetes develop other organ-specific autoimmune diseases, such as celiac disease, Graves disease, hypothyroidism, Addison disease, pernicious anemia, and vitiligo."
]
},
{
"type":"p",
"hlId":"afcd3e",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Treatment"
]
},
" "
]
},
{
"type":"p",
"hlId":"fe6978",
"children":[
"Patients with type 1 diabetes are treated with ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"intensive insulin"
]
},
" therapy, which includes intermediate-acting or long-acting insulin for basal coverage and preprandial analogue or regular insulin injections throughout the day. Intensive insulin therapy can also include continuous subcutaneous insulin infusion with an insulin pump and meal-time boluses."
]
},
{
"type":"p",
"hlId":"6e2b0b",
"children":[
"Basal insulin dose accounts for 50% of the total daily dose of insulin; the remaining insulin is divided to cover the preprandial doses. Examples of ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"basal insulin"
]
},
" options:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"ec9f22",
"children":[
"Insulin glargine, insulin detemir, or insulin degludec: A single 10 ",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"PM"
]
},
" dose controls nocturnal plasma glucose levels and glucose levels between meals. It also counters the early morning rise in glucose level (“dawn phenomenon”) caused by hepatic gluconeogenesis."
]
},
" ",
{
"type":"list-item",
"hlId":"8ee717",
"children":[
"Isophane (",
{
"type":"abbreviation",
"title":"intermediate-acting insulin or Lente",
"children":[
"NPH"
]
},
") intermediate-acting insulin: This insulin can be used in the morning and evening to provide basal plasma insulin levels and to suppress hepatic gluconeogenesis."
]
},
" "
]
},
{
"type":"p",
"hlId":"1a74ee",
"children":[
"Examples of short-acting ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"preprandial insulin"
]
},
" options:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"a92c4d",
"children":[
"Insulin aspart, insulin glulisine, and insulin lispro: rapid-acting insulin given 5 to 15 minutes before meals to modulate the postprandial rise in glucose level."
]
},
" ",
{
"type":"list-item",
"hlId":"0e4edd",
"children":[
"Regular insulin: given 30 minutes before meals to prevent postprandial elevations in blood glucose."
]
},
" "
]
},
{
"type":"p",
"hlId":"6685a1",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Correctional insulin"
]
},
" is the use of additional analogue or regular insulin beyond the usual dose to treat preprandial glucose that is not at target. For example, a correction for type 1 diabetes may be an additional 1 U of insulin for every 50 mg/dL that the glucose level is above the preprandial target."
]
},
{
"type":"p",
"hlId":"e366ee",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Insulin pumps:"
]
},
" Subcutaneous infusion of rapid-acting insulin is delivered continuously for basal insulin requirements and given in intermittent boluses for prandial needs."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_bb_en_s1_inline_t1"
],
"forceOpen":true
},
{
"type":"p",
"hlId":"0f6309",
"children":[
"Hypoglycemia unawareness describes the presence of severely low plasma glucose levels that occur without warning symptoms followed by sudden loss or impairment of consciousness. Treat immediately with rapid-acting carbohydrates or a glucagon injection followed by food. ",
{
"type":"alert",
"children":[
"Lowering the insulin dose and allowing the average plasma glucose level to increase for several weeks may restore sensitivity to hypoglycemia."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_bb_en_s1_2",
"title":{
"__html":"Type 2 Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"5a7aa7",
"children":[
"Type 2 Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"daf10f",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Diagnosis"
]
},
" "
]
},
{
"type":"p",
"hlId":"0935ac",
"children":[
"Type 2 diabetes is characterized by a combination of insulin resistance and a β-cell secretory defect. With time, progressive β-cell dysfunction can develop, leading to absolute insulin deficiency."
]
},
{
"type":"p",
"hlId":"6b0918",
"children":[
"Because symptoms may be subtle, the time to diagnosis may be delayed. Consequently, approximately 20% of patients with type 2 diabetes have microvascular complications of the disease at presentation; an even higher percentage may have ",
{
"type":"abbreviation",
"title":"coronary artery disease",
"children":[
"CAD"
]
},
" or peripheral vascular disease. Most patients with type 2 diabetes are obese or at least have abdominal obesity. Characteristic findings of long-standing diabetes include:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"0d123b",
"children":[
"polyuria, polyphagia, and polydipsia"
]
},
" ",
{
"type":"list-item",
"hlId":"cb0270",
"children":[
"retinal microaneurysms, dot-and-blot hemorrhages, macular edema"
]
},
" ",
{
"type":"list-item",
"hlId":"7bb65f",
"children":[
"symmetric sensory “stocking-glove” peripheral neuropathy"
]
},
" ",
{
"type":"list-item",
"hlId":"bea00b",
"children":[
"cardiovascular and kidney disease"
]
},
" "
]
},
{
"type":"p",
"hlId":"a05526",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Screening for Type 2 Diabetes"
]
},
" "
]
},
{
"type":"p",
"hlId":"b9e7bb",
"children":[
"The ",
{
"type":"abbreviation",
"title":"U.S. Preventive Services Task Force",
"children":[
"USPSTF"
]
},
" recommends screening for abnormal blood glucose as part of cardiovascular risk assessment in adults aged 35 to 70 years who are overweight or obese."
]
},
{
"type":"p",
"hlId":"8ded25",
"children":[
"The ",
{
"type":"abbreviation",
"title":"American Diabetes Association",
"children":[
"ADA"
]
},
" recommends screening adults with overweight (",
{
"type":"abbreviation",
"title":"body mass index",
"children":[
"BMI"
]
},
" ≥25; ≥23 in Asian Americans) with at least one additional risk factor and all patients >35 years. Additional risk factors include:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"75bf6f",
"children":[
"first-degree relative with diabetes"
]
},
" ",
{
"type":"list-item",
"hlId":"241964",
"children":[
"high-risk race/ethnicity (e.g., African American, Latino, Native American, Asian American, Pacific Islander)"
]
},
" ",
{
"type":"list-item",
"hlId":"c9f83f",
"children":[
"history of ",
{
"type":"abbreviation",
"title":"cardiovascular disease",
"children":[
"CVD"
]
}
]
},
" ",
{
"type":"list-item",
"hlId":"800577",
"children":[
"physical inactivity"
]
},
" ",
{
"type":"list-item",
"hlId":"c12974",
"children":[
"hypertension"
]
},
" ",
{
"type":"list-item",
"hlId":"fbb251",
"children":[
"HDL cholesterol level <35 mg/dL and/or triglyceride level >250 mg/dL"
]
},
" ",
{
"type":"list-item",
"hlId":"36226e",
"children":[
" ",
{
"type":"abbreviation",
"title":"polycystic ovary syndrome",
"children":[
"PCOS"
]
},
" "
]
},
" "
]
},
{
"type":"p",
"hlId":"fe68e8",
"children":[
"Screen using the following tests: fasting plasma glucose, 2-hour postprandial glucose during an ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"oral glucose tolerance test",
"children":[
"OGTT"
]
},
","
]
},
" or hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
". If two separate tests are done simultaneously and both are abnormal, diagnose diabetes. If only one of the two tests is abnormal, repeat the abnormal test."
]
},
{
"type":"p",
"hlId":"2a7823",
"children":[
"Patients with a history of gestational diabetes should be tested at least every 3 years. Patients with a history of prediabetes should be tested annually."
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"9f19f4",
"children":[
"A random plasma glucose level ≥200 mg/dL with hyperglycemic symptoms is diagnostic of diabetes and does not warrant repeat measurement."
]
},
" "
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_bb_en_s1_inline_t2"
],
"forceOpen":true
},
{
"type":"p",
"hlId":"afcd3e",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Treatment"
]
},
" "
]
},
{
"type":"p",
"hlId":"c571ed",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Intensive lifestyle modification"
]
},
" (diet, exercise, weight loss) is appropriate for all patients with prediabetes or type 2 diabetes."
]
},
{
"type":"p",
"hlId":"e84c5e",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Medication"
]
},
", such as metformin, reduces the risk of diabetes in patients with prediabetes, although not as effectively as lifestyle interventions."
]
},
{
"type":"p",
"hlId":"52c1f8",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Bariatric procedures"
]
},
" should be considered in patients with obesity."
]
},
{
"type":"p",
"hlId":"a5abcf",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Blood glucose monitoring"
]
},
" includes self-monitoring of blood glucose, hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
", or continuous glucose monitoring."
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"2fc9d0",
"children":[
"Use self-monitoring of blood glucose for patients taking multiple daily injection insulin therapy or continuous subcutaneous insulin infusion therapy."
]
},
" ",
{
"type":"list-item",
"hlId":"a278ae",
"children":[
"Obtain postprandial blood glucose levels in patients with at-goal preprandial readings but with hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" not at goal."
]
},
" ",
{
"type":"list-item",
"hlId":"a6d3fd",
"children":[
"Obtain overnight blood glucose monitoring to detect hypoglycemia or dawn phenomenon."
]
},
" "
]
},
{
"type":"p",
"hlId":"6f6395",
"children":[
"Although guidelines vary, a reasonable individualized goal for most patients is a hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" of 7% to 8%. Goals are adjusted based on patient age and health status."
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"3b4ac5",
"children":[
"If a patient is nonadherent with multiple insulin injections, adherence is unlikely to increase because a pump is prescribed."
]
},
" ",
{
"type":"list-item",
"hlId":"aa7391",
"children":[
"Hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" will be falsely low in patients with hemolytic anemia, patients taking erythropoietin, or patients with kidney injury."
]
},
" "
]
},
{
"type":"p",
"hlId":"292a0e",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Pharmacologic Therapy for Type 2 Diabetes Mellitus"
]
},
" "
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"ba81ba",
"children":[
"Metformin is the recommended first-line oral agent for newly diagnosed type 2 diabetes."
]
},
" ",
{
"type":"list-item",
"hlId":"9b2b2e",
"children":[
"Hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" should be assessed every 3 months with adjustments to therapy until the glycemic target is achieved and every 6 months if at goal."
]
},
" ",
{
"type":"list-item",
"hlId":"9f391a",
"children":[
"If not at goal, next preferred therapy is an ",
{
"type":"abbreviation",
"title":"sodium-glucose transporter-2",
"children":[
"SGLT2"
]
},
" inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist for patients at risk for or with established ",
{
"type":"abbreviation",
"title":"atherosclerotic cardiovascular disease",
"children":[
"ASCVD"
]
},
" or with established kidney disease, and an SGLT2 inhibitor for ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"heart failure",
"children":[
"HF"
]
},
"."
]
}
]
},
" ",
{
"type":"list-item",
"hlId":"921bad",
"children":[
"In most patients who need the greater glucose-lowering effect of an injectable medication, GLP-1 receptor agonists are preferred to insulin."
]
},
" ",
{
"type":"list-item",
"hlId":"f4f157",
"children":[
"If weight loss is a desired effect, GLP-1 receptor agonists and SGLT2 inhibitors are the best choices."
]
},
" "
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_bb_en_s1_inline_t3"
],
"forceOpen":true
},
{
"type":"p",
"hlId":"edbed7",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Screening recommendations for chronic complications of diabetes:"
]
},
" Patients with type 1 and type 2 diabetes should be screened regularly for diabetic complications, including:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"b401c2",
"children":[
"retinopathy (comprehensive eye examination)"
]
},
" ",
{
"type":"list-item",
"hlId":"dbd344",
"children":[
"nephropathy (albumin-to-creatinine ratio)"
]
},
" ",
{
"type":"list-item",
"hlId":"43cbe5",
"children":[
"neuropathy (10 g monofilament, 128-Hz tuning fork, pedal pulses, and ankle reflex)"
]
},
" ",
{
"type":"list-item",
"hlId":"b2a4a7",
"children":[
"CVD (",
{
"type":"abbreviation",
"title":"blood pressure",
"children":[
"BP"
]
},
" and fasting lipid profile measurements)"
]
},
" "
]
},
{
"type":"p",
"hlId":"5f2d15",
"children":[
"Screening for complications in patients with type 1 diabetes should begin at 5 years after diagnosis and should be performed annually thereafter. Screening for complications in patients with type 2 diabetes should begin at the time of diagnosis and be performed annually thereafter."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_bb_en_s1_inline_t4"
],
"forceOpen":true
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_bb_en_f01"
],
"forceOpen":true
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_bb_en_f02"
],
"forceOpen":true
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"a13faf",
"children":[
"Do not treat diabetic mononeuropathy (e.g., third nerve palsy); symptoms resolve spontaneously."
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_en_s1_3",
"title":{
"__html":"Test Yourself"
},
"titleNode":{
"type":"section-title",
"hlId":"7866cc",
"children":[
"Test Yourself"
]
},
"children":[
{
"type":"p",
"hlId":"fa3b21",
"class":"test",
"children":[
"A 29-year-old woman with a 10-year history of type 1 diabetes has nocturnal hypoglycemia. Her insulin schedule includes 24 U NPH insulin/10 U regular insulin before breakfast and 14 U NPH insulin/10 U regular insulin before dinner. Her hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" is 7.2%. What change should be made to her insulin regimen?"
]
},
{
"type":"p",
"hlId":"9b6e82",
"class":"test_answer",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Answer:"
]
},
" ",
"For management, three answers are possible: Delay the NPH insulin until bedtime, lower the evening NPH dose, or (an even better choice) stop the NPH insulin and substitute insulin glargine, detemir, or degludec at bedtime."
]
}
]
}
]
},
"tablesContent":{
"mk19_bb_en_s1_inline_t1":{
"id":"mk19_bb_en_s1_inline_t1",
"number":1,
"bookId":"en",
"title":{
"__html":"Study Table: Adjusting Insulin Dose in Diabetes Mellitus"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"840153",
"children":[
"Study Table: Adjusting Insulin Dose in Diabetes Mellitus"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e2941",
"class":"col hd l",
"children":[
"Condition"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"50fc9b",
"class":"col hd l",
"children":[
"Cause"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea4252",
"class":"cell txt l",
"children":[
"Fasting hyperglycemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"103f41",
"class":"cell txt l",
"children":[
"Not enough basal insulin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b37e7d",
"class":"cell txt l",
"children":[
"Prelunch hyperglycemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"af4d94",
"class":"cell txt l",
"children":[
"Not enough rapid-acting insulin at breakfast or not enough morning NPH insulin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d60bdd",
"class":"cell txt l",
"children":[
"Predinner hyperglycemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b895cb",
"class":"cell txt l",
"children":[
"Not enough rapid-acting insulin at lunch or not enough morning NPH insulin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab3976",
"class":"cell txt l",
"children":[
"Bedtime hyperglycemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6dbacb",
"class":"cell txt l",
"children":[
"Not enough rapid-acting insulin at dinner"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b34d49",
"class":"cell txt l",
"children":[
"Fasting or nocturnal hypoglycemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b47295",
"class":"cell txt l",
"children":[
"Too much basal insulin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"188e79",
"class":"cell txt l",
"children":[
"Prelunch hypoglycemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"24e71d",
"class":"cell txt l",
"children":[
"Too much rapid-acting insulin at breakfast or too much morning NPH insulin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"633c71",
"class":"cell txt l",
"children":[
"Predinner or bedtime hypoglycemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4b91c",
"class":"cell txt l",
"children":[
"Too much rapid-acting insulin at lunch or dinner or too much morning NPH"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_bb_en_s1_inline_t2":{
"id":"mk19_bb_en_s1_inline_t2",
"number":2,
"bookId":"en",
"title":{
"__html":"Study Table: Diagnosis and Classification of Prediabetes and Type 2 Diabetes Mellitus"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"085365",
"children":[
"Study Table: Diagnosis and Classification of Prediabetes and Type 2 Diabetes Mellitus"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"523223",
"class":"col hd l",
"children":[
"Diagnosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"67dcc7",
"class":"col hd l",
"children":[
"Fasting Glucose"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0e1221",
"class":"col hd l",
"children":[
"Random Glucose"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0f5c07",
"class":"col hd l",
"children":[
"2-Hour Glucose during OGTT"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"20d62f",
"class":"col hd l",
"children":[
"Hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0f9337",
"class":"cell txt l",
"children":[
"Prediabetes (increased risk for diabetes) "
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"15f2cb",
"class":"cell txt l",
"children":[
"100-125 mg/dL"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"48ff19",
"class":"cell txt l",
"children":[
"140-199 mg/dL"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"97e943",
"class":"cell txt l",
"children":[
"5.7%-6.4%"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52d261",
"class":"cell txt l",
"children":[
"Diabetes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4e90ec",
"class":"cell txt l",
"children":[
"≥126 mg/dL"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"765881",
"class":"cell txt l",
"children":[
"≥200 mg/dL with symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1ee5c",
"class":"cell txt l",
"children":[
"≥200 mg/dL"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"adce42",
"class":"cell txt l",
"children":[
"≥6.5%"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_bb_en_s1_inline_t3":{
"id":"mk19_bb_en_s1_inline_t3",
"number":3,
"bookId":"en",
"title":{
"__html":"Study Table: Pharmacologic Agents Used to Lower Blood Glucose Levels in Type 2 Diabetes Mellitus"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"19529f",
"children":[
"Study Table: Pharmacologic Agents Used to Lower Blood Glucose Levels in Type 2 Diabetes Mellitus"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5db77f",
"class":"col hd l",
"children":[
"Drug"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8c489d",
"class":"col hd l",
"children":[
"Weight"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"adc4eb",
"class":"col hd l",
"children":[
"ASCVD"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"498ab1",
"class":"col hd l",
"children":[
"HF"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"459fde",
"class":"col hd l",
"children":[
"Kidney Benefit"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a4960",
"class":"cell txt l",
"children":[
"Metformin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6823e8",
"class":"cell txt l",
"children":[
"Possible benefit"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"331b7d",
"class":"cell txt l",
"children":[
"SGLT2 inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"14781e",
"class":"cell txt l",
"children":[
"Loss"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"892665",
"class":"cell txt l",
"children":[
"Benefit (empagliflozin, canagliflozin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6b6c59",
"class":"cell txt l",
"children":[
"Benefit (empagliflozin, canagliflozin, dapagliflozin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6b6c59",
"class":"cell txt l",
"children":[
"Benefit (empagliflozin, canagliflozin, dapagliflozin)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3ec56e",
"class":"cell txt l",
"children":[
"GLP-1 receptor agonists"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"14781e",
"class":"cell txt l",
"children":[
"Loss"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4995b2",
"class":"cell txt l",
"children":[
"Benefit (dulaglutide, liraglutide, semaglutide)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4995b2",
"class":"cell txt l",
"children":[
"Benefit (dulaglutide, liraglutide, semaglutide)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"08c646",
"class":"cell txt l",
"children":[
"DPP-4 inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"36130e",
"class":"cell txt l",
"children":[
"Possible risk, saxagliptin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"394da1",
"class":"cell txt l",
"children":[
"Thiazolidinediones"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"35d72f",
"class":"cell txt l",
"children":[
"Gain"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ad3658",
"class":"cell txt l",
"children":[
"Possible benefit, pioglitazone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"59ca88",
"class":"cell txt l",
"children":[
"Risk"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3b6a82",
"class":"cell txt l",
"children":[
"Second-generation sulfonylureas"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"35d72f",
"class":"cell txt l",
"children":[
"Gain"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"38ef85",
"class":"cell txt l",
"children":[
"Insulin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"35d72f",
"class":"cell txt l",
"children":[
"Gain"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_bb_en_s1_inline_t4":{
"id":"mk19_bb_en_s1_inline_t4",
"number":4,
"bookId":"en",
"title":{
"__html":"Study Table: Treatment of Diabetes Complications"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"8f1b0c",
"children":[
"Study Table: Treatment of Diabetes Complications"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e2941",
"class":"col hd l",
"children":[
"Condition"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4eb417",
"class":"col hd l",
"children":[
"Goal or Indication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4c4ac0",
"class":"col hd l",
"children":[
"Treatment"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"01da3e",
"class":"cell txt l",
"children":[
"Hypertension"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"084470",
"class":"cell txt l",
"children":[
"BP goal <130/80 mm Hg (",
{
"type":"abbreviation",
"title":"American College of Cardiology",
"children":[
"ACC"
]
},
"/",
{
"type":"abbreviation",
"title":"American Heart Association",
"children":[
"AHA"
]
},
" hypertension guideline)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f6b057",
"class":"cell txt l",
"children":[
"All first-line antihypertensive drug classes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d74701",
"class":"cell txt l",
"children":[
"BP goal <140/90 mm Hg (ADA guideline)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b7b6e9",
"class":"cell txt l",
"children":[
"ACE inhibitor or ",
{
"type":"abbreviation",
"title":"angiotensin receptor blocker",
"children":[
"ARB"
]
},
" in patients with albuminuria"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bb3f7f",
"class":"cell txt l",
"children":[
"Diabetes and average cardiovascular risk"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bf3171",
"class":"cell txt l",
"children":[
"Age >40 years, diabetes, and a 10-year ASCVD risk <7.5% (ACC/AHA guideline)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"32f657",
"class":"cell txt l",
"children":[
"Moderate-intensity statin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a46591",
"class":"cell txt l",
"children":[
"Diabetes and increased cardiovascular risk"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"51a7cf",
"class":"cell txt l",
"children":[
"CAD, peripheral vascular disease, or ASCVD risk ≥7.5% (AHA/ACC guideline)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"23bf97",
"class":"cell txt l",
"children":[
"High-intensity statin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0e125",
"class":"cell txt l",
"children":[
"Age 40-75 years, diabetes, and a calculated 10-year risk of a cardiovascular event ≥10% (USPSTF recommendation)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e16c2b",
"class":"cell txt l",
"children":[
"Moderate- to high-intensity statin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b6d0b7",
"class":"cell txt l",
"children":[
"ADA and ACC/AHA recommendation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5e2abd",
"class":"cell txt l",
"children":[
"SGLT2 inhibitor or GLP-1 receptor agonist"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5500d8",
"class":"cell txt l",
"children":[
"Diabetic kidney disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"244bc2",
"class":"cell txt l",
"children":[
"Urine albumin excretion ≥30 mg/g"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d5a01c",
"class":"cell txt l",
"children":[
"ACE inhibitor or ARB, SGLT2 inhibitor, GLP-1 receptor agonist"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"258aff",
"class":"cell txt l",
"children":[
"Diabetic retinopathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1d0243",
"class":"cell txt l",
"children":[
"Proliferative and nonproliferative retinopathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a7d659",
"class":"cell txt l",
"children":[
"Excellent blood glucose and BP control; smoking cessation"
]
},
" ",
{
"type":"p",
"hlId":"3fbba5",
"class":"cell txt l",
"children":[
"Panretinal laser photocoagulation for PDR and severe NPDR"
]
},
" ",
{
"type":"p",
"hlId":"12076b",
"class":"cell txt l",
"children":[
"Intraocular injections of bevacizumab or ranibizumab for severe NPDR and PDR or macular edema"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"96cf41",
"class":"cell txt l",
"children":[
"Diabetic peripheral neuropathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c0d003",
"class":"cell txt l",
"children":[
"Numbness, tingling, burning, heaviness, pain, or sensitivity in stocking-glove distribution"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fab891",
"class":"cell txt l",
"children":[
"Pregabalin, duloxetine, gabapentin, amitriptyline, valproate, or capsaicin cream"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6d8cfc",
"class":"cell txt l",
"children":[
"Sexual dysfunction"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bf0b5b",
"class":"cell txt l",
"children":[
"Erectile dysfunction"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d08ca",
"class":"cell txt l",
"children":[
"Oral phosphodiesterase inhibitor (sildenafil, vardenafil, tadalafil)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c876b0",
"class":"cell txt l",
"children":[
"Gastroparesis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1641c3",
"class":"cell txt l",
"children":[
"Early satiety, nausea and vomiting"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7b28d8",
"class":"cell txt l",
"children":[
"Small feedings; metoclopramide or erythromycin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ee7edc",
"class":"cell txt l",
"children":[
"Diabetic foot"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c74a2f",
"class":"cell txt l",
"children":[
"Ulcer or osteomyelitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"74d59e",
"class":"cell txt l",
"children":[
"See Infectious Disease, Diabetic Foot Infections"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"NPDR = nonproliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy."
]
]
}
}
}